Press Releases

NanoImaging Services Welcomes its First Chief Operating Officer as Company’s Expansion of Talent Continues

NanoImaging Services today announced the hire of its first Chief Operating Officer, Brian Conkle, as the company continues its rapid growth.

Veranex Announces Acquisition of Experien Group

Veranex, the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies.

Panthera steps up its move into oncology trials with more than 12 trials in the pipeline and a prostate trial underway

Many cancer clinical research trials were put on hold during Covid – now Panthera Biopartners and Rutherford Health are working in partnership to accelerate oncology research in order to provide improved care for patients.

ADVANZ PHARMA partners with Ashfield Engage to deliver talent acquisition strategy for European specialty medicine division

Ashfield Engage, part of UDG Healthcare plc, announced that it has partnered with ADVANZ PHARMA to develop and deliver a pan-European talent acquisition programme for ADVANZ PHARMA’s specialty medicine division.

Sensyne Health and Sentara Healthcare Form New Partnership for Ethical Data Sharing and Design of New Clinical Algorithms

Combination of Viral Therapy and T Cell Therapy to Improve The Cure Rate of Cancer

IntegrateRNA Offers High-quality Oligonucleotide Conjuagted to Facilitate Diagnostic and Targeted Drug Delivery

Histobiolab: One-Stop Source for Blood Samples to Support Studying Progress of Disease Processes

Noxopharm Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) has reported pre-clinical data confirming a survival benefit of adding Veyonda® to 177lutetium-PSMA-617 (LuPSMA) treatment in prostate cancer.

Clinical Ink CBO Jonathan Andrus Selected as DTRA Co-Leader

Clinical Ink, a global clinical trial technology company, today announced that CBO Jonathan Andrus has been selected to co-lead the Decentralized Trials & Research Alliance’s (DTRA) Initiative 4B: Collaborate on Regulatory Gaps.

MicrobioSeq Division Releases Viral Metagenomics Services to Study Viruses

Biotium Launches Optimized Solution for Exosome Detection by Flow Cytometry

Biotium Launches Optimized Solution for Exosome Detection by Flow Cytometry

Enveda Biosciences Boosts its Translational Capabilities with Two Key Hires

BioIVT Opens New, Larger UK Blood Donor Center on Imperial College London’s White City Campus

BioIVT’s new blood donor center is located in White City, a biotech hub, together with cell therapy, gene therapy, and pharmaceutical companies.

Thermo Fisher Scientific and UC Davis Launch Center of Excellence in Clinical Metabolomics

Thermo Fisher Scientific today announced their collaboration with the UC Davis West Coast Metabolomics Center to form The Center of Excellence in Clinical Metabolomics.

Protheragen MedAI Fully Supports In Vitro Pharmacology Research for Drug Discovery

Flywheel and HealthMyne Partner to Provide End-to-End Radiomic Data Management and Analysis

Flywheel and Healthmyne: Combined technology solution to accelerate radiomics research and clinical trial outcomes

CD Formulation Launches a Full Range of Drug Analysis Services for the Pharmaceutical Industry

Alfa Chemistry Materials Announces a New Product Offering of Quantum Dots

Rho to Coordinate Study Sponsored by NIAID to Assess Systemic Allergic Reactions to Pfizer and Moderna COVID-19 Vaccines

Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, today announced it is coordinating a study called Systemic Allergic Reactions to SARS-CoV-2 Vaccination to assess the proportion of participants with a systemic allergic reaction to the Pfizer-BioNTech and Moderna COVID-19 vaccines in populations at high risk for allergic reaction compared to a general population. This research will be important for further understanding potential risk factors for an allergic reaction to these particular vaccines, as well as to future vaccines that similarly use an mRNA nanoparticle platform. The study is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).